Change over period: —
NSE · AKUMS
AKUMS
-13.0% from the 52-week high · +73.0% above the low
Akums Drugs & Pharmaceuticals Ltd manufactures and distributes pharmaceutical products including injectables, generics, and hospital supplies. The company ensures high-quality standards and regulatory compliance.
The short version. AKUMS reported revenue of ₹1,342 crore for Sep 2026, up 31.8% from a year earlier. Net profit was ₹113 crore (up 175.6% year on year). Return on equity was 7.7% in Mar 2026. Promoter holding was 75.26% in Sep 2026, up 0.00 points over 8 quarters.
1 · The price
How has the stock traded?
AKUMS trades 13.0% below its 52-week high and 73.0% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹1,342 cr.
Sep 2026 net profit of ₹113 cr.
4.4 pts higher than a year earlier.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1342 | 1167 | 1158 | 1160 | 1018 | 1024 | 1056 | 1010 |
| Net profit | 113 | 100 | 85 | 66 | 41 | 63 | 148 | 65 |
| Net margin % | 8.4 | 8.6 | 7.3 | 5.7 | 4.0 | 6.2 | 14.0 | 6.5 |
| EPS (₹) | 7.17 | 6.35 | 5.38 | 4.21 | 2.59 | 4.03 | 9.38 | 4.14 |
Annual
| FY2026 | FY2025 | |
|---|---|---|
| Revenue | 4359 | 4118 |
| Net profit | 255 | 338 |
| Net margin % | 5.9 | 8.2 |
| EPS (₹) | 16.21 | 21.49 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 7.7% in Mar 2026; debt to equity is 0.02.
Profitability · 2 years
Returns and margins
| Mar 2026 | Mar 2025 | |
|---|---|---|
| Return on equity % | 7.7 | 11.1 |
| Return on capital % | 10.9 | 11.8 |
| EBITDA margin % | 14.1 | 12.8 |
| Net margin % | 5.7 | 8.1 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | — | — |
| Profit CAGR | — | — |
4 · The owners
Who holds it, and are they adding?
Unchanged over 8 quarters.
Down 1.86 pts over 8 quarters.
Up 4.08 pts over 8 quarters.
+4 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 75.26 | 75.26 | 75.26 | 75.26 | 75.26 | 75.26 | 75.26 | 75.26 | 0.0 |
| FII | 6.36 | 5.77 | 4.24 | 2.28 | 1.15 | 1.37 | 1.91 | 4.5 | -1.86 |
| DII | 7.0 | 7.4 | 8.85 | 9.28 | 14.4 | 14.35 | 13.44 | 11.08 | +4.08 |
| Public | 8.65 | 8.85 | 8.93 | 10.46 | 6.46 | 6.29 | 6.66 | 6.43 | -2.22 |
Mutual fund holdings · Oct 2026
23 schemes hold this stock
19 the month before.
- Old Bridge Flexi Cap Fund2.35% of NAV
- Franklin India Opportunities Fund2.02% of NAV
- Templeton India Value Fund1.83% of NAV
- ICICI Prudential Healthcare Fund1.65% of NAV
- Franklin India Multi Cap Fund1.56% of NAV
- Franklin India Small Cap Fund1.16% of NAV
- SAMCO SPECIAL OPPORTUNITIES FUND1.12% of NAV
- NIPPON INDIA PHARMA FUND1.09% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for AKUMS are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about AKUMS
What is the AKUMS share price?
AKUMS (AKUMS) last closed at ₹712.85, down 0.46% on the day. Its 52-week range is ₹414.05 to ₹823.30.
What is the market cap of AKUMS?
AKUMS has a market capitalisation of about ₹10,964 crore. Its price-to-earnings ratio is 30.3.
How are AKUMS's latest results?
AKUMS reported revenue of ₹1,342 crore for Sep 2026, up 31.8% from a year earlier. Net profit was ₹113 crore (up 175.6% year on year). Return on equity was 7.7% in Mar 2026. Promoter holding was 75.26% in Sep 2026, up 0.00 points over 8 quarters.
Who owns AKUMS?
As of Sep 2026, shareholding was: Promoter 75.26%, FII 4.5%, DII 11.08%, Public 6.43%.
How many mutual funds hold AKUMS?
23 mutual fund schemes held AKUMS in October 2026. That compares with 19 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 03 Jul 2026 · Final Dividend - Rs. 1
- 03 Jul 2026 · Special Dividend - Rs. 2
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.